Current tests are based on quantifying the cell-mediated immune response using either skin induration from tuberculin skin testing (TST) or ex vivo interferon-γ (IFN-γ) reactivity to Mtb-specific antigens by IFN-γ release assays (IGRA).8 LTBI, encompassing individuals who are Mtb-sensitized, therefore may represent diverse immune responses to tuberculosis including eliminated, controlled or subclinical infection.1,2 How these immune states relate to glucose metabolism, including diabetes risk, has not been addressed. This evidence concerns the gene IFNG and diabetes mellitus.